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Abstract. In cancers, apoptosis signaling pathways and cell 
survival and growth pathways responsible for resistance 
to conventional treatments, such as Pi3K/Akt/mTOR and 
mitogen-activated protein kinase (MAPK) become dysregu-
lated. Recently, alternative treatments to promote tumor cell 
death have become important. The present study reports on 
the antitumor and cytoprotective action of gold nanoparticles 
(GNPs) and carvedilol in combination and in isolated appli-
cation. Apoptosis was analyzed by FITC/propidium iodide 
staining flow cytometry; caspase-3, caspase-8, Bcl-2 and 
MAPK/ERK activity by immunofluorescence microscopy; 
gene expression of proteins related to cell death as Akt, 
mTOR, EGFR, MDR1, survivin, FADD and Apaf, by the 
real-time PCR; and western blot analysis for MAPK/ERK, 
Akt and mTOR. Oxidative stress evaluation was performed 
by reduced glutathione (GSH) and malondialdehyde (MDA) 
levels. Intracellular GNPs targets were identified by transmis-
sion electron microscopy. After exposure to a combination of 
GNPs (6.25 µg/ml) and carvedilol (3 µM), death as promoted 
by apoptosis was detected using flow cytometry, for expres-
sion of pro-apoptotic proteins FADD, caspase-3, caspase-8 and 
sub-regulation of anti-apoptotic MAPK/ERK, Akt, mTOR, 
EGFR and MDR1 resistance. Non-tumor cell cytoprotection 
with GSH elevation and MDA reduction levels was detected. 
GNPs were identified within the cell near to the nucleus 
when combined with carvedilol. The combination of GNP 
and carvedilol promoted downregulation of anti-apoptotic 
and drug resistance genes, over-regulation of pro-apoptotic 
proteins in tumor cells, as well as cytoprotection of non-tumor 
cells with reduction of apoptosis and oxidative stress.
Introduction
Cancer, a serious public health problem worldwide, is respon-
sible for countless deaths each year and is currently considered 
the second leading cause of death on the planet (1-3). In addi-
tion, various malignant tumor types do not have effective 
treatment (4-8), due to the ability of tumor cells to evade 
death, by presenting changes in apoptosis pathway protein 
levels (9-11). Changes in other cellular pathway proteins 
such as Pi3k/Akt/mTOR and MAPK/ERK, which are highly 
dysregulated in malignant tumors, also corroborate the ability 
of malignant cells to evade apoptosis death, contributing to 
chemotherapy resistance (12-14). The expression of multi-
drug resistance genes, such as MDR1, has been implicated 
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as the main cause of chemoresistance (15,16). Furthermore, 
conventional chemotherapeutic treatments are known for their 
side-effects on non-tumor cells, such as the strong oxidative 
stress (17-19).
Moreover, there is a need for alternative treatments that 
promote apoptosis in tumor cells and yet do not negatively affect 
normal cells. In this regard, GNPs have been highlighted in the 
literature as promising agents with large pooling surfaces for 
various drugs (20), which concentrate on tumor tissues (21,22), 
are resistant to corrosion and present low toxicity to the 
biological system (23-25). In addition, various studies reported 
an effective antitumor action with non toxicity to normal 
cells (26-29). The antihypertensive carvedilol is often used as 
a non-selective inhibitor of adrenergic receptors (30), is known 
for its cardiovascular and antioxidant benefits (31-34) and has 
recently presented good antitumor activity, such as growth 
inhibition of neuroblastoma cell lines (35) and rat glioma cell 
line (36), suppressing migration and invasion of malignant 
breast cells (37), preventing carcinogenesis in rat epidermal 
lineages (38) and promoting apoptosis in tumoral hepatic and 
oral cell linages (39,40). The discovery of new substances and 
combinations is fundamental to the process of establishing new 
treatments against cancer (41-43). Combining substances has 
proven to be extremely effective due to the lower doses used, 
the decreased adverse effects, and the possibility of acting on 
different signaling pathways (44-50). In addition, the discovery 
of substances that promote inhibition of dysregulated pathways 
such as Pi3k/Akt/mTOR and MAPK/Erk would positively 
modulate apoptosis in tumor cells (12,51,52). In the present 
study, we investigated the effects of combined carvedilol and 
GNPs action on both tumor and non-tumor cells.
Materials and methods
Reagents. The reagents were purchased as indicated: Dulbecco's 
modified Eagle's medium (DMEM; Life Technologies, Grand 
Island, NY, USA); 10% (v/v) heat-inactivated fetal bovine 
serum (FBS; Cultilab Materiais para Cultura de Células Ltda, 
Campinas, Brazil); trypsin/ EDTA (ethylenediaminetetraacetic 
acid) (Gibco-BRL, Life Technologies, Grand Island, NY, USA); 
cisplatin (citoplax, 50 mg; Bergamo, Taboão da Serra, Brazil); 
gold nanoparticles GNPs (Institute of Chemical, UFRN, 
Natal, Brazil); carvedilol (Farmafórmula, Natal, Brazil); gold 
(III) chloride (30% wt. in HCl), sodium hydroxide, glycerol, 
and polyvinylpyrrolidone (PvP, molecular weight, 10,000 Da) 
were products from Sigma-Aldrich. The synthesis and charac-
terization of GNPs was the described by de Araújo et al (53). 
GNPs, carvedilol and cisplatin solutions were filtered using a 
0.22-mm minipore membrane.
Cell culture. The human cell lines hepatocellular carcinoma 
(HepG2) and human non-cancerous renal cell line (HEK-293) 
were purchased from the Culture Collection of the Federal 
University of Rio de Janeiro (RJCB Collection, Rio de Janeiro, 
Brazil). HepG2 and Hek-293 cells were maintained in DMEM 
supplemented with 10% (v/v) heat-inactivated FBS.
Cell viability. In order to determine GNP and carvedilol doses to 
promote and maintain low inhibition in cancer cells, cell viability 
was determined by trypan blue exclusion assay. The viability was 
determined at 24 and 48 h for HepG2 (1x105 cells) at different 
concentrations of GNPs (1-50 µg/ml, aqueous suspension) and 
carvedilol [1.5-300 µM, dissolved in dimethyl sulfoxide (DMSO) 
1%]. The cells were placed into 6-well plates. Briefly, cell aliquots 
were mixed with the same volume 0.5% (w/v) trypan blue and 
incubated at room temperature for 5 min. The number of viable 
cells was calculated using a hemocytometer.
Annexin V and propidium iodide staining. The apoptotic assay 
was conducted according to Araújo Jr et al (54). HepG2 and 
HEK-293 were plated in 6-well plates (2x105 cells/well) with 
2 ml medium/well. After 24 h, concentrations of GNPs (3 and 
6.25 µg/ml), cisplatin (15 µg/ml) and carvedilol (1.5 and 3 µM) 
were added (24 and 48 h), respectively. In parallel, control cells 
were maintained in culture medium without GNPs, carvedilol 
or cisplatin. For observation of combined action, the cells were 
treated with GNPs (3 and 6.25 µg/ml) and at 24 h treated with 
carvedilol (1.5 and 3 µM). After another 24 h, they were analyzed. 
The cells were then assayed using the Annexin v-FITC/PI 
apoptosis detection kit I (BD Biosciences, San Diego, CA, USA). 
Annexin v-FITC and propidium iodide (PI) were added to the 
cellular suspension according to the manufacturer's instructions. 
A total of 1x106 cells from each sample was then analyzed by 
FACSCalibur cytometer (BD Biosciences, Franklin Lakes, NJ, 
USA), and FlowJo software (BD Biosciences). Annexin v-FITC-
positive/PI-negative cells were identified as cells in the early 
stages of apoptosis, while Annexin v-FITC-positive/PI-positive 
cells were identified as cells in the late stages of apoptosis, or as 
cells undergoing necrosis.
Glutathione (GSH) levels. Antioxidant GSH levels in cell 
lines were measured [adapted from Rahman et al (55) and 
Costa et al (56)]. HepG2 and Hek-293 were plated in 6-well 
plates (2x105 cells/well) with 2 ml medium/well. After 24 h, 
GNPs (6.25 µg/ml) was added and after 24 h, 3 µM carvedilol. 
A homogenate of cells (100 µl of cell in 500 µl EDTA 0.02 M) 
were added to 320 µl of distilled water and 80 µl of 50% trichlo-
roacetic acid (TCA). Samples were centrifuged at 3,000 rpm 
for 15 min at 4˚C. The supernatant (100 µl) was added to 200 µl 
of 0.4 M Tris buffer at pH 8.9 and 20 µl of 0.01 M 5,5'-dithiobis 
(2-nitrobenzoic acid) (DTNB). The absorbance of each sample 
was measured at 420 nm, in a spectrophotometric/microplate 
reader Polaris and the results were reported as units of GSH 
per milligram.
Malondialdehyde levels. Malondialdehyde (MDA) is an end 
product of lipid peroxidation. To quantify the increase in 
free radicals in non-cancer (HEK-293) and cancer (HepG2) 
cells, MDA content was measured via the assay described by 
Esterbauer and Cheeseman (57). Cell samples were suspended 
in buffer; Tris HCl 1:5 (w/v), and minced with scissors for 
15 sec on an ice-cold plate. The resulting suspension was 
homogenized for 2 min with an automatic Potter homogenizer 
and centrifuged at 11,000 rpm at 4˚C for 10 min. The super-
natants were assayed in order to determine the MDA content. 
The absorbance of each sample was measured at 586 nm. The 
results are expressed as nanomoles of MDA per cell.
Immunofluorescence, Bcl-2, MAPK/ERK, caspase-3 and 
caspase-8 activity. HepG2 cells were plated on glass 
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coverslips in 24-well plates (5x104 cells/well). After 24 h, they 
were treated with the GNPs (6.25 µg/ml), cisplatin (15 µg/ml) 
and carvedilol (3 µM) for 48 h. For combined action, we used 
GNPs (6.25 µg/ml) + carvedilol (3 µM). The cells were then 
washed, and fixed with paraformaldehyde, permeabilized by 
Triton-X, and incubated with anti-Bcl-2 mouse polyclonal 
antibody, rabbit polyclonal anti-caspase-3 antibody (Abcam, 
San Francisco, CA, USA), rabbit anti-caspase-8 monoclonal 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), 
and monoclonal mouse antibody anti-MAPK/ERK (Invitrogen, 
Carlsbad, CA, USA) diluted 1:500 in phosphate-buffered 
saline (PBS) containing bovine serum albumin (BSA; 5%; Life 
Technologies do Brasil Ltda, São Paulo, Brazil) for 1 h at RT 
in a humid atmosphere. The primary antibody was detected 
with Alexa Fluor 488 goat anti-rabbit or anti-mouse secondary 
antibody (Abcam), and 4',6-diamidino-2-phenylindole (Life 
Technologies do Brasil Ltda) was used for nuclear staining. 
The immunostained coverslips were examined under Axio 
Observer z.1, inverted fluorescence and brightfield.
Fluorescent images were obtained on a Carl zeiss Laser 
Scanning Microscope (LSM 710, 20X objectives; Carl zeiss, 
Oberkochen, Germany). Negative controls and treated groups 
were included in each batch of samples. Cell reactivity in all 
groups (negative, GNPs, carvedilol, GNPs + carvedilol and 
cisplatin) was assessed by computerized densitometric analysis 
of the captured digital images with the aforementioned immu-
nofluorescence microscope. Average densitometric values 
were calculated in ImageJ software (http://rsb.info.nih.gov/ij/). 
Contrast index measurements were obtained from the formula 
[(selected area x 100)/total area] after removal of background 
in regions of interest (three samples per group).
Real-time PCR. HepG2 cells were plated in 6-well plates 
(2x105 cells/well) with 2 ml medium/well. After 24 h, concen-
trations of gold nanoparticles (6.25 µg/ml), cisplatin (15 µg/ml) 
and carvedilol (3 µM) were added for 48 h. For combined 
action, GNPs (6.25 µg/ml) + (3 µM) carvedilol was used. The 
cells were collected with cell scrapers and total RNA was 
isolated from cells using TRIzol reagent. The total RNA was 
extracted from cell samples using RNeasy Mini kit (Qiagen, 
Tokyo, Japan) from QIAcube following the manufacturer's 
guidelines. The total RNA extracted underwent reverse tran-
scriptase activity using the High capacity RNA-to-cDNA kit 
(Applied Biosystems, Ltd., Tokyo, Japan). Real-time quantita-
tive PCR analyses of EGFR, Akt, mTOR, survivin, MDR-1, 
FADD, Apaf-1 and GAPDH mRNAs were performed with 
SYBR-Green Mix in the Applied Biosystems® 7500 FAST 
system (Applied Biosystems, Foster City, CA, USA), according 
to a standard protocol with the following primers: GAPDH 
(forward, 5'-AAC TTT GGC ATC GTG GAA GG-3' and 
reverse, 5'-GTG GAT GCA GGG ATG ATG TTC-3', annealing 
primer temperature, 60˚C); EGFR (forward, 5'-TGA TAG 
ACG CAG ATA GTC GCC-3' and reverse, 5'-TCA GGG CAC 
GGT AGA AGT TG-3', annealing primer temperature, 56.6˚C); 
Akt (forward, 5'-ACG GCA TGG ACT TTA CCA AG-3' and 
reverse, 5'-GCG GGT GAA AGA CAG GAA TA-3', annealing 
primer temperature, 55˚C); mTOR (forward, 5'-TTG AGG 
TTG CTA TGA CCA GAG AGA A-3' and reverse, 5'-TTA 
CCA GAA AGG ACA CCA GCC AAT G-3', annealing primer 
temperature, 58.3˚C); survivin (forward, 5'-TAC AGC TTC 
GCT GGA AAC CT-3' and reverse, 5'-AGC CCG GAT GAT 
ACA AAC AG-3', annealing primer temperature, 55.6˚C); 
MDR1 (forward, 5'-GTG TGG TGA GTC AGG AAC CTG 
TAT-3' and reverse, 5'-TCT CAA TCT CAT CCA TGG TGA 
CA-3', annealing primer temperature, 57˚C); FADD (forward, 
5'-TCT CCA ATC TTT CCC CAC AT-3' and reverse, 5'-GAG 
CTG CTC GCC TCC CT-3', annealing primer temperature, 
58.7˚C); and Apaf-1 (forward, 5'-CCT CTC ATT TGC TGA 
TGT CG-3' and reverse, 5'-TCA CTG CAG ATT TTC ACC 
AGA-3', annealing primer temperature, 56.9˚C). The experi-
ments were performed in triplicate. The standard PCR 
conditions were as follow: 50˚C for 2 min and 95˚C for 10 min, 
followed by 40 of 30-sec cycles at 94˚C, a variable annealing 
primer temperature for 30 sec and at 72˚C for 1 min. Mean Ct 
values were used to calculate the relative expression levels of 
the target genes for the experimental groups as relative to 
those in the negative control group; expression data were 
normalized relative to the housekeeping gene GAPDH using 
the 2-ΔΔCt formula.
Western blot analysis. Cells (HepG2) were lysed in buffer 
[Tris-HCl 50 mM, NaCl 150 mM, Triton X-100 1%, EDTA 
1 mM, sodium pyrophosphate 20 mM, pH 7.4 containing a 
protease inhibitors cocktail (Roche), NaF (10 mM), DTT 
(1 mM), PMSF (0.1 mM) and sodium vanadate (1 mM)] on 
ice. To confirm equal loadings, total protein concentration was 
determined using the Bradford method (Bio-Rad Laboratories, 
Hercules, CA, USA). Proteins were resolved using SDS-PAGE 
and then transferred to a polyvinylidene diflouride (PVDF) 
membrane. Non-specific binding sites on the membrane were 
blocked using 5% non-fat skimmed milk and incubated with 
the primary antibody anti-Akt (1:500; Abcam), anti-mTOR 
(1:500; Abcam), and MAPK/ERK (1:200; Abcam), overnight 
at 4˚C, followed by incubation with the appropriate secondary 
antibodies: Akt α-rat peroxidase 1:1,000; mTOR-rabbit 
peroxidase 1:2,000 and MAPK/ERK α-rat peroxidase 1:1,000. 
Proteins were detected using the ECL Plus kit (Perkin-Elmer, 
San Jose, CA, USA).
Transmission electronic microscopy (TEM). Cells (HepG2) 
at a density of 3x105 were plated into (GNPs sensitized and 
treated) 6-well plates, and after 48 h were collected with 
trypsin, centrifuged at 1,500 rpm for 5 min, and washed 
with PBS. The cell pellet was fixed with 2.5% glutaralde-
hyde + paraformaldehyde 4% + sodium cacodylate buffer 
(0.1 M) for 4 h at 4-8˚C. Afterwards, the samples were washed 
in 0.05 M sodium cacodylate (3x30 min), post-fixed in 1% 
OsO4 + 1% potassium ferrocyanide (2 h), washed again (3x) 
with 0.05 M sodium cacodylate (3x30 min), and then serially 
dehydrated in ethanol 50, 70, 90 and 100, for 30 min each. 
Polymerization of the resin was performed at 60˚C for 48 h. 
Finally, ultramicrotomy was performed followed by staining 
(uranyl acetate 1% + 1% lead citrate 1 h), and electron micro-
scope visualization (Tescan transmission, vega 3 model).
Statistical analysis. All experiments were performed in tripli-
cate, and the significant differences between the groups were 
calculated using the analysis of variance and the Bonferroni's 
test, as indicated. A P<0.05 was considered statistically 
significant.
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Figure 1. Cell viability to determine the cell growth. (A) Effect of different doses of GNPs on hepatic tumor cells (HepG2) at 24 and 48 h. The 12.5 µg/ml 
dose caused greater cellular growth inhibition at both times. (B) Effect of different doses of carvedilol on hepatic tumor cells (HepG2) at 24 and 48 h. Doses 
>6.25 µM promoted strong inhibition of cell growth. *P<0.05; ***P<0.001.
Figure 2. Flow cytometry to determine the cell death for apoptosis. Effect of different doses of GNPs, carvedilol, and cisplatin on early and late apoptosis in 
HepG2 cells. (A-F) At 24 h and (G-N) at 48 h. Control (A and G), GNPs 3 µg/ml (B and H), GNPs 6.25 µg/ml (C and I), Carv 1.5 µM (D and J), Carv 3 µM 
(E and K), cisplatin 15 µg/ml (F and L). GNPs 3 µg/ml + Carv 1.5 µM (M) and GNPs 6.25 µg/ml + Carv 3 µM (N). (O) Early apoptosis and (P) late apoptosis. 
*P<0.05, **P<0.01 and ***P<0.001.
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Results
Cell viability. The GNPs doses 1, 3 and 6.25 µg/ml, at 
24 h (Fig. 1A) promoted low inhibition of cellular viability. 
The other GNPs doses promoted greater cellular growth 
inhibition, when compared to lower doses. The most signifi-
cant was 12.5 µg/ml (P<0.05). At 48 h, GNPs doses of 3 
and 6.25 µg/ml maintained low inhibition similar to that at 
24 h (Fig. 1A), and for GNPs doses of 1, 25 and 50 µg/ml, 
there was cellular growth when compared to the same doses 
at 24 h. The carvedilol doses that promoted low inhibition of 
cellular viability were 1.5 and 3 µM at 24 h (Fig. 1B). The other 
carvedilol doses promoted greater cellular growth inhibition 
(P<0.001). At 48 h, the 1.5 and 3 µM carvedilol doses main-
tained low inhibition (Fig. 1B). The other doses of carvedilol 
promoted greater cellular growth inhibition (P<0.001). DMSO 
at 1% was used as the carvedilol vehicle.
Detection of apoptosis, by flow cytometer. For HepG2 
cells, combined treatment (GNP 6.25 µg/ml + carvedilol 
3 µM) induced early (P<0.05) and late (P<0.001) apoptosis 
at 48 h (Fig. 2O-P). The isolated dose of carvedilol (3 µM) 
induced early apoptosis at 48 h (Fig. 2O; P<0.01). GNPs 
(6.25 µg/ml) induced late apoptosis at 48 h, P<0.05. Doses of 
GNPs and carvedilol did not induce statistically significant 
apoptosis in non-tumor cells (Fig. 3). Combined treatment 
Figure 3. Flow cytometry to determine cell death by apoptosis. Effect of different doses of GNPs, carvedilol, and cisplatin on early and late apoptosis in HEK-
293 cells at 24 h (A-F) and 48 h (G-N). Control (A and G), GNPs 3 µg/ml (B and H), GNPs 6.25 µg/ml (C and I), Carv 1.5 µM (D and J), Carv 3 µM (E and K), 
cisplatin 15 µg/ml (F and L). GNPs 3 µg/ml + Carv 1.5 µM (M) and GNPs 6,25 µg/ml + Carv 3 µM (N). (O) Total apoptosis. *P<0.05.
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Figure 4. Oxidative stress markers. (A) GSH measurement, important protein in balance of oxidative stress. The combined treatment modulated GSH levels 
on HEK-293 (*P<0.05; **P<0.01 and ***P=0.0003) and HepG2 (*P<0.05; **P<0.01 and ***P<0.0001). (B) MDA measurement, indirect marker of oxidative stress. 
After combined treatment with GNPs and Carv, there was a reduction of the statistically significant levels of malondialdehyde in tumor and non-tumoral lines. 
*P<0.05; **P<0.01.
Figure 5. Detection of caspase-3, caspase-8, Bcl-2 and MAPK/ERK. HepG2 cells stained with DAPI (blue), anti-caspase-3, anti-caspase-8, anti-Bcl-2, and 
anti-MAPK/ERK antibodies (green) (A). Caspase-3 and caspase-8 were detected in all treated groups, yet MAPK/ERK was not. Bcl-2 did not alter expres-
sion. Contrast index for caspase-3, *P<0.05 and **P<0.01 (B); caspase-8, ***P<0.001 and #P>0.05 (C); Bcl-2, #P>0.05 and ***P<0.001 (D) and MAPK/ERK, 
****P<0.0001 (E). All groups treated with GNPs + Carv showed high immunoreactivity for caspase-3, caspase-8 and low immunoreactivity for MAPK/ERK.
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(GNP 6.25 µg/ml + carvedilol 3 µM) promoted cytoprotec-
tion (P<0.05; Fig. 3O). when HepG2 and HEK-293 cells 
were treated with 15 µg/ml cisplatin, apoptosis was detected 
at 24 and 48 h after treatment (Figs. 2F and L and 3F and L, 
respectively). The goal of using a non-tumor cell is to have as 
a control a non-tumoral lineage to analyze its behavior against 
the treatment. HEK-293 is used to study cytotoxicity because 
of its reliable growth despite its karyotype complex with altera-
tions. This makes toxicity studies more consistent (54,58-62).
Oxidative stress. The reduced glutathione and lipid peroxi-
dation levels were observed from GSH and MDA assays, 
respectively. Due to the fact that the combined treatment with 
GNPs (6.25 µg/ml) + carvedilol (3 µM), at 48 h increased the 
protection for HEK-293, it was observed that the levels of GSH 
increased statistically significantly for both HEK-293 (P<0.05) 
and HepG2 (P<0.001), as shown in Fig. 4A. Cisplatin promoted 
reduction of GSH levels in both cell lines. Regarding lipid 
peroxidation for the non-tumoral lineage, there was a great 
reduction in malondialdehyde levels using the combined treat-
ment with GNPs (6.25 µg/ml) + carvedilol (3 µM) (P<0.01), 
overcoming the control and cisplatin treated groups. This 
same result was observed for the HepG2 tumor cells (Fig. 4B).
Immunofluorescence of caspase-3, caspase-8, Bcl-2 and 
MAPK/ERK. After combined treatment with GNPs (6.25 µg/ml) 
+ carvedilol (3 µM), caspase-3 and caspase-8 marking was 
noted in all treated groups (Fig. 5A). Densitometric analysis 
confirmed significant increases in caspase-3 (P<0.01; Fig. 5B), 
and caspase-8 (P<0.001; Fig. 5C). In addition, there was no 
statistically significant change in Bcl-2 expression for the 
group treated with GNPs and carvedilol (Fig. 5D; P>0.05). 
There was a decrease in MAPK/ERK immunoreactivity in 
the HepG2 cells treated with GNPs and carvedilol and GNP 
(6.25 µg/ml) + carvedilol (3 µM) for 48 h (P<0.0001; Fig. 5E). 
Gene and protein expression by RT-PCR and western blot 
analysis. From the gene expression analysis, it was observed 
that FADD elevation was statistically significant for all 
groups, those treated separately with GNPs (6.25 µg/ml) and 
carvedilol (3 µM) (P<0.05), and in combined treatment GNPs 
(6.25 µg/ml) + carvedilol (3 µM) (P<0.01), yet not observed 
Figure 6. Gene and protein expression. Relative expression of genes related to survival and tumor resistance by real-time PCR. (A) FADD and Apaf-1, *P<0.05 
and **P<0.01; (B) surviving and MDR1, *P<0.05 and **P<0.01; (C) EGFR, Akt and mTOR, *P<0.05, **P<0.01, ***P<0.001. (D) western blot analysis of proteins 
related to survival and tumor proliferation. After exposure to the GNPs and carvedilol combination, there was a large decrease in the protein levels of Akt. 
mTOR and MAPK/ERK have a good reduction. β-actin was used as internal control. Lane 1, Control; lane 2, GNP 6.25 µg/ml + Carv 3 µM.
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for APAF-1 levels (Fig. 6A). In relation to survivin levels, no 
group treated with GNPs and carvedilol demonstrated a reduc-
tion, meanwhile MDR-1 levels showed statistically significant 
reductions for those treated with GNPs (6.25 µg/ml), and 
for combined treatment GNPs (6.25 µg/ml) + carvedilol 
(3 µM) (P<0.01; Fig. 6B). Regarding the Akt, mTOR and 
EGFR levels, the groups treated with combined treatment 
GNPs (6.25 µg/ml) + carvedilol (3 µM) showed statistically 
significant expression declines P<0.001, P<0.05 and P<0.05, 
respectively (Fig. 6C). The groups treated with carvedilol 
(3 µM) showed statistically significant reductions only for 
EGFR (P<0.01); and those treated with GNP showed statisti-
cally significant reductions only for Akt (P<0.05) and EGFR 
(P<0.05).
The anti-apoptotic protein levels after combined treatment 
of GNPs (6.25 µg/ml) + carvedilol (3 µM) are highlighted 
in Fig. 6D. The results showed a large reduction of Akt and 
mTOR. MAPK/ERK has a good reduced protein expression 
when compared to the control group. β-actin was used as 
internal control.
Transmission electron microscopy. TEM was performed 
in order to ascertain locations where gold nanoparticles 
would concentrate, applied without carvedilol (Fig. 7A) and 
in combination with carvedilol (Fig. 7B). Applied alone, 
GNPs (6.25 µg/ml) was concentrated in the vicinity of the 
plasma membrane. In the combined treatment with GNPs 
(6.25 µg/ml) + carvedilol (3 µM), GNPs displayed intra-nuclear 
and perinuclear concentration.
Discussion
Data from the literature demonstrate the importance of using 
low doses for drug combination studies that aim to reduce 
side-effects and increase the field of action in different 
signaling pathways (63-65). In the present study, low doses 
of GNPs (3 and 6.25 µg/ml) and carvedilol (1.5 and 3 µM) 
were selected using the cell viability test, in order to use them 
in combination. Studies in the literature demonstrate that low 
doses of GNPs are more effective in inhibiting cell prolifera-
tion than larger doses (53,66). In relation to carvedilol, very 
high doses cause high inhibition of cell growth (67); a risk for 
a combined treatment. The pro-apoptotic activities of GNPs, 
carvedilol, and their combined use were analyzed by flow 
cytometry, both for tumor and non-tumoral lines. The combi-
nation of GNPs (6.25 µg/ml) + carvedilol (3 µM) promoted 
significant initial and late apoptosis in hepatic tumor cells, 
while promoting reduction of total apoptosis in the non-tumoral 
lineage. Studies in the literature report the ability of GNPs to 
induce apoptosis in several tumor cell lines without interfering 
with non-tumoral lineages (27,29,68,69). Carvedilol has itself 
also been shown to be an inducer of apoptosis in tumor cells 
and to protect normal cells (36,70,71).
The cytoprotective effect of the combined treatment for 
non-cancerous cells was evidenced through GSH dosage; an 
important balancing antioxidant system peptide (72,73). After 
treatment, GSH levels were elevated, which is important for 
reducing oxidative stress, which is related to apoptosis induc-
tion in several tissues (74-77). In addition, GNPs and carvedilol 
have the ability to promote elevation of GSH levels (78-81). 
Furthermore, a decrease in MDA levels were evidenced, an 
indirect biomarker for oxidative stress, as related to plasma 
membrane damage (82-84). This is a significant result, since 
one of the main side-effects of chemotherapy is lipid peroxida-
tion (85,86).
In the tumoral lineage, we observed GSH level elevation and 
decreased MDA levels, demonstrating the antioxidant action 
of combined treatment when compared to cisplatin, which is 
known for its strong oxidative stress promotion (18,19). This 
result was highly positive, since tumor cells have high rates 
of reactive oxygen species, which trigger the activation of 
proteins such as Pi3K, Akt and MAPK/ERK; responsible for 
both cell proliferation and survival (87,88).
The pro-apoptotic activity of the treatment was confirmed 
by the positive immunoreactivity of caspase-3 and caspase-8, 
proteins involved in the extrinsic apoptosis pathway (89), 
these were the most significant in the group treated with 
the combination. In addition, after treatments with GNPs 
(6.25 µg/ml) + carvedilol (3 µM), there was a decrease in 
immunoreactivity for the MAPK/ERK, anti-apoptotic protein. 
A similar result is observed in western blot analysis. There 
were no significant changes for Bcl-2. These results indicate 
a prominent participation of the extrinsic apoptosis pathway, 
since Bcl-2 is an anti-apoptotic protein related to the intrinsic 
apoptosis pathway (mitochondrial) (54,90). GSH elevation and 
Figure 7. Transmission electron microscopy for evaluation of intracellular 
targets of treatment. (A) GNPs without carvedilol concentrated in the plasma 
membrane, indicated by black arrows. (B) For combined treatment, GNPs 
concentrated inside and beside the nucleus, indicated by black arrows. N, 
nucleus. 
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MDA decreases, promoted by the combined treatment with 
GNPs (6.25 µg/ml) + carvedilol (3 µM), may have corrobo-
rated with mitochondria protection, justifying non-activation 
of the intrinsic apoptosis pathway (91-96). The statistically 
significant elevation of FADD, mainly by combined treatment 
with GNPs (6.25 µg/ml) + carvedilol (3 µM), confirms activa-
tion of the extrinsic apoptosis pathway, since it participates 
therein (97-99). Levels of APAF-1, a protein involved in the 
intrinsic pathway (100), did not present a significant differences.
The combined treatment with GNPs (6.25 µg/ml) + 
carvedilol (3 µM) was extremely effective on gene expression 
of anti-apoptotic proteins such as Akt and mTOR, matching 
or overcoming the action of cisplatin. Similar effect was 
observed in western blot analysis. Inhibition of these proteins, 
as well as MAPK/ERK, is critical for induction of apop-
tosis (12,51,52,101). Furthermore, other studies indicate that 
treatments with targeting of the Pi3K/Akt/mTOR pathway 
and the MAPK/ERK protein induce early and late apop-
tosis (102-104), as also obtained in the present study.
The decrease in EGFR levels is of great relevance since it is 
related to activation of Akt/mTOR and MAPK/ERK (105-108). 
However, it is possible that the combined treatment may be 
acting on EGFR-independent pathways that activate Akt and 
mTOR; and causing depletion (14,109-115). Levels of survivin 
were unchanged for treatment. However, in the same figure, 
there was a statistically significant reduction in MDR1 levels 
for both the combined treatment and the gold nanoparticles 
alone. Studies have shown that the use of nanoscale systems has 
excellent effects (this includes inorganic nanoparticles, such as 
gold nanoparticles), on the expression of genes related to multi-
drug resistance, such as MDR1 (116,117). The decrease in the 
expression of this protein presents potential as a new strategy 
to combat one of the main problems of cancer treatment, resis-
tance to treatment (118). Carvedilol, although showing no effect 
on MDR1 expression, has been reported in the literature as a 
potential MDR1 inhibitor (119,120). Studies in the literature 
have demonstrated that treatments acting on drug resistance 
genes promote both early and late apoptosis (121).
TEM did reveal GNPs internalization. However, we noted 
that when given alone, GNPs accumulated near the plasmatic 
membrane. Previous studies have reported that endosomal/
lysosomal vesicles can imprison GNPs preventing complete 
action in the cellular interior, and are the greatest barrier that 
GNPs need to overcome to reach the cellular nucleus (main 
target) (122-125). However, after administration of carvedilol, 
concentration of GNPs was observed in the vicinity of the 
cell nucleus, both intra- and peripherally. The data possibly 
explain the fact that the results for GNPs administered alone 
show smaller indices as compared to the combined treatment, 
which was more effective. But even the isolated action of the 
gold nanoparticle can reduce, although less than combined 
treatment, the levels of survival and proliferation proteins 
such as Akt, EGFR, MDR-1 and MAPK/ERK, demonstrated 
in the present study, and suggest the way in which the GNPs 
inhibit proliferation. Concerning the combined treatment, 
carvedilol may be acting through other signaling pathways, or 
may be facilitating gold nanoparticle escape from endosomal/
lysosomal vesicles. Han et al (126) reported that carvedilol has 
a role during receptor recycling in endosomal/lysosomal tran-
siting of vascular smooth muscle cell beta-adrenergic receptors. 
However, there remains the need for further chemical interac-
tion and intracellular unfolding studies.
The present study demonstrated the ability of the combined 
GNPs and carvedilol treatment to induce apoptosis in the 
tumor cells by exclusively activating the extrinsic pathway. 
Activation of this pathway is advantageous compared to the 
intrinsic pathway, since it can be triggered independently of 
the p53 gene, which in many tumors is inactive or absent (127). 
In addition, studies have demonstrated that treatments with 
targeting intrinsic pathway induction may also promote posi-
tive selection of tumor cells, while evading the mitochondrial 
pathway (128). In addition to these results, the combined treat-
ment protected non-tumor cells, reducing oxidative stress and 
consequently, apoptosis. The novel findings in these studies 
highlight a promising alternative for future cancer treatments.
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